1. Darvishian M, van den Heuvel ER, Bissielo A, et al. Effectiveness of seasonal influenza vaccination in community-dwelling elderly people: An individual participant data meta-analysis of test-negative design case-control studies. Lancet Respir Med 2017;5(3):200–11.
2. Beyer WEP, McElhaney J, Smith DJ, et al. Cochrane re-arranged: Support for policies to vaccinate elderly people against influenza. Vaccine 2013;31(50):6030–33.
3. Schultze V, D’Agosto V, Wack A, et al. Safety of MF59 adjuvant. Vaccine 2008;26(26):3209–22.
4. Calabro S, Tortoli M, Baudner BC, et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 2011;29(9):1812–23.
5. Khurana S, Verma N, Yewdell JW, et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011;3(85):85ra48.
6. Boikos C, Imran M, Nguyen VH, et al. Effectiveness of the adjuvanted influenza vaccine in older adults at high risk of influenza complications. Vaccines 2021;9(8):862.
7. Mcconeghy KW, Davidson HE, Canaday DH, et al. Cluster-randomized trial of adjuvanted Versus nonadjuvanted trivalent influenza vaccine in 823 US nursing homes. Clin Infect Dis 2021;73(11):e4237–43.
8. Coleman BL, Sanderson R, Haag MDM, Mcgovern I. Effectiveness of the MF59‐adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta‐analysis. Influenza Other Respir Viruses 2021;15(6):813–23.
9. Imran M, Puig-Barbera J, Ortiz JR, et al. Relative effectiveness of MF59® adjuvanted trivalent influenza vaccine versus non-adjuvanted vaccines during the 2019-2020 influenza season. Open Forum Infectious Diseases 2022;ofac167.
